Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal

Arrowhead Pharmaceuticals shifts focus to subcutaneous platform after abandoning lead hepatitis B program and related products due to toxicity concerns, resolving to lay off 30% of staff.